Status:
UNKNOWN
Microparticles Circulating Plasma Concentration in Atrial Fibrillation After Percutaneous Occluding of the Left Atrium
Lead Sponsor:
Institut Mutualiste Montsouris
Collaborating Sponsors:
Société Française de Cardiologie
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
The aim of the study is to compare levels of differnts types of microparticles circulating before and after percutaneous occluding of the left atrium by patients with atrial fibrillation and patients ...
Eligibility Criteria
Inclusion
- atrial fibrillation group:
- high embolic risk (CHADS-VASC2 score ≥4)
- formal and final contraindication to anticoagulant therapy
- no heart thrombus on ETO and TDM before percuraneous occluding
- control group:
- suspicion of stable coronary artery disease, coronary angiography scheduled and double platelet aggregation (clopidogrel and aspirine)
Exclusion
- for both groups
- congestive heart failure, severe aortic stenosis, EP or TVP early.
Key Trial Info
Start Date :
January 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2018
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03361202
Start Date
January 1 2015
End Date
March 1 2018
Last Update
December 4 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Mutualiste Montsouris
Paris, France, 75014